Firm & Final

Stop Loss and Supplemental Benefits | Drew Neslin & Liz Midtlien

While the world of stop loss often focuses on mitigating catastrophic employer risk, supplemental health products are designed to protect the working families at the heart of those plans. In this episode of Firm & Final, we explore these "two sides of the same coin," examining how these two distinct product lines manage different layers of risk in an increasingly expensive healthcare landscape. We’re joined by two of our BCS Financial colleagues: Liz Midtlien, Head of Large Claims Solutions; and Drew Neslin, Head of Supplemental Health Solutions.  Together, we break down the similarities and differences between these markets and how they can work in tandem to support both employers and employees. Tapping into the depth of their individual experiences, Liz and Drew define some of the features that make supplemental insurance unique, explore the contrasting market challenges that the two industries face, and chart the potential for "claims integration," where medical data is used to automatically trigger supplemental benefit payments.  Finally, our guests offer their predictions for the coming year, from industry consolidation and market exits to the "doubling down" on technology and transparency to better serve the needs of the modern workforce. 🖥️ Play on BCS website – https://bcsf.com/firmandfinalpodcast/  🎧 Listen on Spotify – https://spoti.fi/3U7rYuq  🍎 Listen on Apple Podcasts – https://apple.co/3Kvdlhg  ☑️ Sign up to subscribe – https://bcsf.com/firmandfinalpodcast/  🦸 Recommend a Legend – legends@bcsf.com

Capital Markets Vs. Insurance Markets | Theresa Galizia, Tara Krauss, Alexis Neu

It feels like there's a growing disconnect between established players in the stop loss industry and the new entrants who crop up annually.  Long-term industry experts point to warning signs that the market may be hardening.  Yet every year, new players enter the market, attracted by the undeniable year-over-year growth.  So what are they seeing on both sides of this equation that creates this disconnect between the insurance markets and the capital markets? And where are we all going to end up?  In this episode, we bring in three pros to sort it all out: Theresa Galizia from Berkley Accident and Health, Tara Krauss from QBE North America, and Alexis Neu from Guy Carpenter. Additionally, they'll discuss why it's so rare to see an all-female panel in our industry, and what can be done about that.  And then, why one panelist predicts the stop loss industry will eclipse $50 billion next year! 🖥️ Play on BCS website – https://bcsf.com/firmandfinalpodcast/  🎧 Listen on Spotify – https://spoti.fi/3U7rYuq  🍎 Listen on Apple Podcasts – https://apple.co/3Kvdlhg  ☑️ Sign up to subscribe – https://bcsf.com/firmandfinalpodcast/  🦸 Recommend a Legend – legends@bcsf.com

How Big Consulting Firms Influence Stop Loss & Reinsurance | Laurie Horan LeBlanc, Andrew Peel, Carol Adams

You can't fully understand the stop loss and reinsurance industry without considering the impact that its myriad consultants have on both insurers and underwriters.  These consultants bring decades of experience to bear on behalf of their clients, and offer up a unique perspective on what's happening behind the scenes in our business.  So in this episode of Firm & Final, we'll introduce you to three of the industry's foremost experts from the consulting side—Laurie Horan LeBlanc from Marsh McLennan, Andrew Peel from Mercer, and Carol Adams from Guy Carpenter.  We'll discuss the current market dynamics, the challenges faced by stop loss carriers, and the appeal of the market to new entrants. As consultants in the industry, Laurie, Andrew and Carol will also share how they evaluate new providers and make recommendations to their clients, claims management issues, and the growing role of captives in the market.  Finally, each participant in the conversation will offer advice for clients as they prepare for the 2026 renewals season. 🖥️ Play on BCS website – https://bcsf.com/firmandfinalpodcast/  🎧 Listen on Spotify – https://spoti.fi/3U7rYuq  🍎 Listen on Apple Podcasts – https://apple.co/3Kvdlhg  ☑️ Sign up to subscribe – https://bcsf.com/firmandfinalpodcast/  🦸 Recommend a Legend – legends@bcsf.com

Meeting the Needs of the Reinsurance Market | Bob Black, Raj Gulati, Tanya Arrowsmith

It’s summer time—normally the calm before the storm for the stop loss and reinsurance industries.  But many experts will tell you the industry feels more “unsettled” than usual.  It’s a time of churn, as some carriers exit but other new players enter. Some stop loss carriers are struggling to find margin, while some brokers feel like they’re in a strong position.  So in this episode, we want to chart a path for meeting the needs of the stop loss and reinsurance industries amid this market uncertainty. We’re talking to three experts from the front lines: Tanya Arrowsmith from Crum & Forster, Bob Black from Aon Benfield, and Raj Gulati from Risk Strategies Company.    They’ll explore the dynamics of capacity and profitability, the impact of market cycles, the influx of new entrants, and the ongoing trends of consolidation within the industry. 🖥️ Play on BCS website – https://bcsf.com/firmandfinalpodcast/  🎧 Listen on Spotify – https://spoti.fi/3U7rYuq  🍎 Listen on Apple Podcasts – https://apple.co/3Kvdlhg  ☑️ Sign up to subscribe – https://bcsf.com/firmandfinalpodcast/  🦸 Recommend a Legend – legends@bcsf.com

The State of Gene Therapy in Stop Loss | Ashley Hume, Brooks Wildasin & Kelly Munger

Gene therapy offers a powerful tool for treating or curing debilitating diseases that have vexed medical science for years. Patients battling conditions like hemophilia B, sickle cell anemia, beta thalassemia, Duchenne muscular dystrophy and other ailments now have new options to consider in their treatment plans. But let's be blunt. Gene therapy is also... at least for now... really, REALLY expensive. And so, as these incredible treatments and technologies are unveiled, those of us in the stop loss and reinsurance industries have to stay informed about new developments in gene therapy, the implications of insurance for gene therapy, and the greater economic and social forces in play. To help us explore these topics, we're bringing in expertise from Ashley Hume, President of Emerging Therapy Solutions; Brooks Wildasin, Chief Product and Innovation Officer at Havarti Risk; and Kelly Munger, Head of US Health at PartnerRe.  🖥️ Play on BCS website – https://bcsf.com/firmandfinalpodcast/ [https://bcsf.com/firmandfinalpodcast/ ] 🎧 Listen on Spotify – https://spoti.fi/3U7rYuq [https://spoti.fi/3U7rYuq] 🍎 Listen on Apple Podcasts – https://apple.co/3Kvdlhg [https://apple.co/3Kvdlhg ] ☑️ Sign up to subscribe – https://bcsf.com/firmandfinalpodcast/ [https://bcsf.com/firmandfinalpodcast/ ] 🦸 Recommend a Legend – legends@bcsf.com